129 related articles for article (PubMed ID: 15994271)
1. Increased disease activity in a patient with sarcoidosis after high dose interleukin 2 treatment for metastatic renal cancer.
Logan TF; Bensadoun ES
Thorax; 2005 Jul; 60(7):610-1. PubMed ID: 15994271
[TBL] [Abstract][Full Text] [Related]
2. High-dose interleukin-2 immunotherapy is safe for patients with metastatic renal cell carcinoma on dialysis.
Brusky JP; Gailani F; Pathak A; Patel H; Aboseif S
BJU Int; 2006 Feb; 97(2):279-80. PubMed ID: 16430629
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
4. Clinical pathways for managing patients receiving interleukin 2.
Mavroukakis SA; Muehlbauer PM; White RL; Schwartzentruber DJ
Clin J Oncol Nurs; 2001; 5(5):207-17. PubMed ID: 11905416
[TBL] [Abstract][Full Text] [Related]
5. Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer.
Acquavella N; Kluger H; Rhee J; Farber L; Tara H; Ariyan S; Narayan D; Kelly W; Sznol M
J Immunother; 2008; 31(6):569-76. PubMed ID: 18528297
[TBL] [Abstract][Full Text] [Related]
6. Recurrence of pemphigus vulgaris associated with interleukin 2 therapy.
Prussick R; Plott RT; Stanley JR
Arch Dermatol; 1994 Jul; 130(7):890-3. PubMed ID: 7794299
[TBL] [Abstract][Full Text] [Related]
7. High-dose interleukin-2 in metastatic disease: renal cell carcinoma and melanoma.
Dutcher J
Oncology (Williston Park); 2002 Nov; 16(11 Suppl 13):3. PubMed ID: 12469933
[No Abstract] [Full Text] [Related]
8. [Second-line thalidomide/IL-2 therapy in metastatic kidney cancer--results of a pilot study].
Schrader AJ; Heidenreich A; Hegele A; Olbert P; Varga Z; Hofmann R
Aktuelle Urol; 2006 Nov; 37(6):429-35; quiz 423-4. PubMed ID: 17099831
[TBL] [Abstract][Full Text] [Related]
9. [Two cases of renal cell carcinoma with ascites after interleukin-2 therapy].
Kobori G; Maegawa M; Ushida H; Maekawa S; Inoue K; Kaneko Y; Ohmori K; Nishimura K
Hinyokika Kiyo; 2002 Jul; 48(7):455-7. PubMed ID: 12229188
[TBL] [Abstract][Full Text] [Related]
10. Continuous cardiac output and hemodynamic monitoring: high temporal correlation between plasma TNF-alpha and hemodynamic changes during a sepsis-like state in cancer immunotherapy.
Caorsi C; Quintana E; Valdés S; Muñoz C
J Endotoxin Res; 2003; 9(2):91-5. PubMed ID: 12803881
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-2 based immunotherapy in patients with metastatic renal cell carcinoma.
Donskov F
Dan Med Bull; 2007 Nov; 54(4):249-65. PubMed ID: 18208677
[TBL] [Abstract][Full Text] [Related]
12. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
Kato Y; Yoshimura K; Shin T; Verheul H; Hammers H; Sanni TB; Salumbides BC; Van Erp K; Schulick R; Pili R
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4538-46. PubMed ID: 17671140
[TBL] [Abstract][Full Text] [Related]
13. Myositis following treatment with high dose interleukin-2 for malignancy.
Finger DR; Plotz PH; Heywood G
J Rheumatol; 1995 Nov; 22(11):2188. PubMed ID: 8596171
[No Abstract] [Full Text] [Related]
14. Transfusion-related acute lung injury (TRALI) following platelet transfusion in a patient receiving high-dose interleukin-2 for treatment of metastatic renal cell carcinoma.
Medeiros BC; Kogel KE; Kane MA
Transfus Apher Sci; 2003 Aug; 29(1):25-7. PubMed ID: 12877889
[TBL] [Abstract][Full Text] [Related]
15. Biotherapy skin reaction.
Newton S; Jackowski C; Marrs J
Clin J Oncol Nurs; 2002; 6(3):181-2. PubMed ID: 11998617
[No Abstract] [Full Text] [Related]
16. Interleukin-2 therapy of metastatic renal cell carcinoma--predictors of response.
McDermott DF; Atkins MB
Semin Oncol; 2006 Oct; 33(5):583-7. PubMed ID: 17045087
[TBL] [Abstract][Full Text] [Related]
17. Severe myocarditis following high-dose interleukin-2 administration.
Samlowski WE; Ward JH; Craven CM; Freedman RA
Arch Pathol Lab Med; 1989 Aug; 113(8):838-41. PubMed ID: 2787976
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib-induced erythema multiforme in metastatic renal cell carcinoma.
Bilaç C; Müezzinoğlu T; Ermertcan AT; Kayhan TC; Temeltaş G; Oztürkcan S; Temiz P
Cutan Ocul Toxicol; 2009; 28(2):90-2. PubMed ID: 19514932
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma.
Amato RJ; Morgan M; Rawat A
Cancer; 2006 Apr; 106(7):1498-506. PubMed ID: 16475152
[TBL] [Abstract][Full Text] [Related]
20. Metastatic renal cancer and patient survival as a criterion of treatment response.
Stathopoulos GP; Koutantos J; Rigatos SK; Stathopoulos J; Batzios S; Batziou C
Oncol Rep; 2008 Feb; 19(2):477-81. PubMed ID: 18202797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
